HUMA Aug 2024 5.000 put
| Previous close | 1.2300 |
| Open | 1.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 5.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.1500 - 1.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | 363 |
GlobeNewswireHumacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
– Third RMAT designation by FDA for ATEV – – RMAT will expedite development of ATEV in PAD – DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, has been granted the U.S. Food and Drug Administration’s (FDA’s) Regenerative Medicine Advanced Therapy (RMAT) designation for patients with advanced peripheral artery disease (PAD). This RMAT de
- GlobeNewswire
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human primate models of BVP implantation showed islet survival and continued insulin production – DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
- GlobeNewswire
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantabl
